

Human Regulatory T Cells Kill Tumor Cells through Granzyme-Dependent Cytotoxicity upon Retargeting with a Bispecific Antibody

Bryan D. Choi^{1,2}, Patrick C. Gedeon^{1,3}, James E. Herndon II⁴, Gary E. Archer¹, Elizabeth A. Reap¹, Luis Sanchez-Perez¹, Duane A. Mitchell^{1,2,5}, Darell D. Bigner^{2,5}, and John H. Sampson^{1,2,5}

Abstract

A major mechanism by which human regulatory T cells (T_{reg}) have been shown to suppress and kill autologous immune cells is through the granzyme-perforin pathway. However, it is unknown whether T_{regs} also possess the capacity to kill tumor cells using similar mechanisms. Bispecific antibodies (bscAb) have emerged as a promising class of therapeutics that activate T cells against tumor antigens without the need for classical MHC-restricted T-cell receptor (TCR) recognition. Here, we show that a bscAb targeting the tumor-specific mutation of the EGF receptor, EGFRvIII, redirects human $CD4^+CD25^+FoxP3^+$ T_{regs} to kill glioblastoma cells. This activity was significantly abrogated by inhibitors of the granzyme-perforin pathway. Notably, analyses of human primary glioblastoma also displayed diffused infiltration of granzyme-expressing $FoxP3^+$ T cells. Together, these data suggest that despite their known suppressive functions, tumor-infiltrating T_{regs} possess potent cytotoxic mechanisms that can be co-opted for efficient tumor cell lysis. *Cancer Immunol Res*; 1(3); 163–7. ©2013 AACR.

Introduction

Despite maximal surgical resection, dose-intensive radiotherapy and multimodal chemotherapy, glioblastoma remains uniformly lethal with a median survival of less than 15 months (1). Novel therapies are desperately needed to improve the prognosis of this disease and immunologic targeting of tumor-specific mutations has emerged as a promising approach (2).

A major barrier that has impeded translation of efficacious immunotherapy is the inability to overcome profound immunosuppression associated with malignant disease (3). Regulatory T cells (T_{regs}) in particular are thought to play a central role in tumor escape from immune-mediated rejection. One mechanism by which T_{regs} are known to suppress and even kill autologous immune cells is through the granzyme-perforin pathway (4, 5). Despite this well-characterized cytotoxic capacity, whether T_{regs} can co-opt cytotoxic mechanisms to kill tumor cells has yet to be evaluated.

T-cell-activating bispecific antibodies (bscAb), particularly those of the bispecific T-cell engager (BiTE) subclass, represent a new therapeutic strategy that has the potential to treat even bulky, invasive disease (6, 7). BiTEs are tandem single-chain

molecules that possess dual specificity for tumor-associated surface antigens and the CD3 complex on T cells, which allows them to divalently bind and afford potent, specific target cell lysis (8). Because CD3 is universally expressed among T cells, BiTEs have the theoretical capacity to redirect and activate even T_{regs} that are elevated and present in tumors of patients with cancer.

Among the few known tumor-specific antigens, perhaps the most widely characterized is the truncated mutant EGF receptor variant type III (EGFRvIII). EGFRvIII is a constitutively activated tyrosine kinase that is frequently expressed on the surface of glioblastoma and other common neoplasms but is completely absent from healthy tissues (9).

In this study, we show that an EGFRvIII-specific BiTE, bscEGFRvIIIxCD3 (7), successfully redirects highly purified T_{regs} and activates them in the presence of tumors expressing EGFRvIII. Despite their known suppressive properties, purified $CD4^+CD25^+CD127^{dim/-}$ T cells efficiently lysed EGFRvIII-expressing glioblastoma *in vitro* upon redirection and activation with bscEGFRvIIIxCD3. This activity was found to be dependent on the granzyme-perforin pathway. Immunohistochemical (IHC) analysis from human primary GBMs also displayed diffuse infiltration of activated, granzyme-producing $FoxP3^+$ cells, showing that T_{regs} with potent effector functions may already be present in tumors even under natural conditions.

Previous efforts to enhance antitumor immunity via T_{reg} depletion have been limited, in part due to an inability to efficiently eliminate suppressive cells that infiltrate tumor tissue (10). Alternatively, our data suggest that BiTEs can activate even suppressive T_{regs} to lyse tumor cells by redirecting their natural granzyme-mediated cytotoxic potential. These findings not only highlight a new mechanism by which

Authors' Affiliations: ¹Duke Brain Tumor Immunotherapy Program, Division of Neurosurgery, Department of Surgery, Departments of ²Pathology, ³Biomedical Engineering, and ⁴Bioinformatics and ⁵Biostatistics and Bioinformatics, and ⁵The Preston Robert Tisch Brain Tumor Center at Duke, Duke University Medical Center, Durham, North Carolina

Corresponding Author: John H. Sampson; Duke Brain Tumor Immunotherapy Program, Division of Neurosurgery, Department of Surgery; Duke University Medical Center; Box 3050; Durham, NC 27710. Phone: 919-684-9043; Fax: 919-419-1741; E-mail: john.sampson@duke.edu

doi: 10.1158/2326-6066.CIR-13-0049

©2013 American Association for Cancer Research.

BiTEs may circumvent certain aspects of T_{reg} -mediated suppression, but also have broader implications with regard to the natural functional role of activated, tumor-infiltrating T_{regs} that express granzyme and perforin in the tumor microenvironment.

Materials and Methods

Tumor cell lines and reagents

The human glioma cell line U87MG and its subline U87MG. Δ EGFR, which expresses EGFRvIII, are described elsewhere and were kind gifts from Dr. Webster Cavenee at University of California, San Diego (11). EGFRvIII expression was verified by flow cytometry using the L8A4 antibody (12). These cell lines were regularly confirmed to be *Mycoplasma*-free by nucleic acid hybridization assay (GEN-PROBE MTC-NI). Characterization, production, and purification of bscEGFRvIIIxCD3 as well as control antibody constructs were conducted as previously described by us (7). Antibodies to CD4 (RPA-T4), CD25 (M-A251), CD69 (L78), CD152 (BNI3), Granzyme A (CB9), Granzyme B (GB11), and Perforin (δ G9) were purchased from BD Biosciences. Anti-FoxP3 antibody (PCH101) and the FoxP3 Staining Buffer Set were purchased from eBioscience and intracellular staining was conducted according to manufacturer's instructions. Antibodies against human FoxP3 (259D, BioLegend) and granzyme B (Cat No. ab4059) were used for IHC staining.

T_{reg} isolation and preparation

All human samples were obtained at Duke University Medical Center (Durham, NC) from individuals who had given written, informed consent. Human PBMCs were prepared by density gradient centrifugation from buffy coats of healthy donor leukapheresis. Highly purified regulatory T cells were isolated from PBMCs by magnetic separation using the CD4⁺CD25⁺CD127^{dim/-} Regulatory T Cell Isolation Kit II and AutoMACS Separator (Miltenyi Biotec) according to the manufacturer's instructions. Following isolation, purity was confirmed by flow cytometric analysis to be more than 95% (CD25⁺FoxP3⁺). Where noted, purified T_{regs} were prepared with the T_{reg} Expansion Kit (Miltenyi Biotec) at a MACSiBead Particle-to- T_{reg} ratio of 4:1 according to manufacturer instructions, with recombinant interleukin 2 (rIL-2) at 500 U/mL, without rapamycin. Cells were verified for their suppressive ability *in vitro* before all cytotoxicity assays.

In vitro activation and functional assays

Activation, proliferation, cytokine secretion, and measures of specific lysis were conducted as previously described by us (7). In assays assessing activation and proliferation, freshly thawed and sorted lymphocytes were incubated in 96-well round-bottom plates with 1×10^4 target tumor cells and EGFRvIII BiTE [E:T ratio, 20:1; incubation time, 48 hours at 37°C; (bscEGFRvIIIxCD3), 10 μ g/mL] in a total volume of 200 μ L. Supernatant was removed after incubation and analyzed by cytometric bead array analysis according to manufacturer instructions (BD Biosciences). Cells were also harvested and assessed for surface and activation markers as above. In experiments assessing proliferation 1 μ Ci, ³H-thymidine was

added to each well of a 96-well round-bottom plate for an additional 24 hours and cells were collected by a cell harvester. Counts were conducted using a Wallac 1450 Microbeta Trilux Liquid Scintillation/Luminescence Counter (Perkin-Elmer). Similarly, cytotoxicity assays were conducted by a standard chromium release assay as previously described by us (7). In brief, target cells were labeled with ⁵¹Cr and incubated with EGFRvIII BiTE and effector cells [E:T ratio, 20:1; incubation time, 18 hours at 37°C; (bscEGFRvIIIxCD3), 10 μ g/mL] in a total volume of 200 μ L. Following incubation, supernatants were removed and measured by gamma counter. Where noted, for inhibition of the granzyme-perforin axis, concanamycin A (CMA, 100 nmol/L; Sigma), Granzyme B Inhibitor I (Z-AAD-CMK, 50 μ mol/L; Calbiochem), or ethylene glycol tetracetic acid (EGTA, 4 mmol/L; Calbiochem) was added to each well. Inhibitor concentrations were chosen based on previously published studies to establish dependence of cell-mediated cytotoxicity on perforin-granzyme activity (4, 13, 14). Before use, each inhibitor was found to have insignificant effects on the viability of T_{regs} following 18 hours incubation at 37°C as assessed by LIVE/DEAD Fixable Violet Dead Cell Stain Kit (Invitrogen). Blockade of FasL- and TRAIL-mediated apoptosis was carried out with antibody clones NOK-1 (25 μ g/mL; BD Biosciences) and RIK-2 (25 μ g/mL; BD Biosciences), respectively.

Immunohistochemistry

Tissues for IHC analysis were derived from human brain tumor biopsy material. Paraffin-embedded tissues were fixed, cut into 5 μ m sections, mounted on glass slides and subjected to primary and secondary staining using the MACH 2 Double Stain 1 polymer Detection Kit (Biocare Medical) according to the manufacturer's instructions. Diaminobenzidine (DAB) and AminoEthyl Carbazole (AEC) were used to detect granzyme B and FoxP3, respectively.

Statistical analysis

Groups were compared using a two-sample two-tailed *t* test and statistical significance was determined at a value of $P < 0.05$.

Results and Discussion

The EGFRvIII BiTE, bscEGFRvIIIxCD3, has previously been shown to redirect polyclonal T-cell populations against EGFRvIII-expressing gliomas (7); however, whether this BiTE also signals activation of FoxP3⁺ T_{regs} , which are not only elevated among tumor-infiltrating lymphocytes (15) but also known to possess potent suppressive properties in the setting of glioblastoma (16), is currently unknown. To evaluate the impact of the EGFRvIII BiTE on human T_{regs} , we first isolated naturally occurring human T_{regs} according to phenotypic CD4⁺CD25⁺CD127^{dim/-} expression (17) and cultured these cells in the presence of EGFRvIII BiTE and glioma cells expressing EGFRvIII (U87MG. Δ EGFR). A control BiTE directed against a nonspecific antigen was also tested to exclude the possibility that the CD3-binding portion of bscEGFRvIIIxCD3 alone was sufficient for activation. After 24 hours, T cells were harvested and examined for surface and intracellular activation markers.

In line with previous literature, isolation of CD4⁺CD25⁺CD127^{dim/-} cells yielded a highly pure population of T cells expressing elevated levels of transcription factor FoxP3, consistent with the phenotypic definition of the T_{reg} subset (18) (Fig. 1A). Following coculture with target cells expressing EGFRvIII, flow cytometric analysis of sorted T_{regs} showed that, in the presence of control BiTE, surface activation markers CD69 and CD25 remained unchanged. However, in wells cultured with EGFRvIII BiTE, T_{regs} exhibited significant upregulation of both early activation associated glycoprotein, CD69, as well as IL-2 receptor alpha chain, CD25 (Fig. 1B). These results were also consistent on repeat using sorted T_{regs} isolated from three separate healthy donors (*P* < 0.05; Fig. 1C). On the basis of this evidence of activation, we also sought to determine functional characteristics of T_{regs} stimulated by the EGFRvIII BiTE in the presence of tumor. Importantly, we found that following BiTE-mediated activation, T_{regs} remained refractory both in terms of their ability to produce inflamma-

tory cytokines (Fig. 1D) and proliferate when compared with CD4⁺CD25⁻ helper T cells (T_H; Fig. 1E). Together, these results indicate that although the EGFRvIII BiTE clearly has the capacity to activate T_{regs}, the functional outcome of this activation may be similar to what would otherwise be expected through standard TCR-restricted engagement of T_{regs} *in vitro*.

Despite their lack of classical proinflammatory mechanisms, it is well-known that even naturally activated T_{regs} possess significant cytotoxic capacity, largely through the production of high levels of granzyme B expression (19). In fact, the perforin-granzyme axis is a major mechanism by which T_{regs} are known to suppress immune responses, through the direct killing of effector T cells (4, 13). Given this well-characterized cytotoxic function, we hypothesized that the EGFRvIII BiTE might actually have the ability to co-opt the perforin-granzyme axis in T_{regs} to kill cells other than lymphocytes, resulting in the redirected lysis of even tumor cells expressing a target antigen of interest, in this case EGFRvIII.

To test this hypothesis, we first sought to evaluate the impact of bscEGFRvIIIxCD3-mediated activation on the expression of perforin and granzymes among T_{regs} in the presence of target tumor cells expressing EGFRvIII. Using flow cytometric analysis of CD4⁺CD25⁺FoxP3⁺ cells, we found that T_{regs} cultured with control BiTE and target tumor cells expressed only low levels of perforin, granzyme A (GrA), and granzyme B (GrB). However, T_{regs} activated in the presence of bscEGFRvIIIxCD3 exhibited significant upregulation of these cytotoxic molecules (Fig. 2A). These results were repeated with consistent and significant upregulation of GrA, GrB, and perforin in samples isolated from three separate healthy donors (*P* < 0.05; Fig. 2B). Moreover, when analyzed for surface markers, back-gating analysis of GrB-positive cells (dots) displayed a distinct population with dual positivity for T_{reg} phenotypic markers, FoxP3 and CD25 (Fig. 2C). The level of FoxP3 expression did not appear to change significantly when gating for T_{regs} with either high or low levels of GrB (data not shown). Although the impact of BiTEs on T_{reg} expression of GrB has not been previously described, these results are consistent with previous studies which have shown substantial GrB upregulation in T_{regs} on stimulation with anti-CD3 antibody (5), which in theory provides the same signal delivered through the T-cell engaging arm of bscEGFRvIIIxCD3.

Because of the significant upregulation of the perforin-granzyme pathway in BiTE-activated T_{regs}, we next decided to test whether the EGFRvIII BiTE could redirect the cytotoxic payload expressed in T_{regs} to lyse target tumor cells expressing EGFRvIII. CD4⁺CD25⁺CD127^{dim/-} T cells were expanded between 4 and 7 days to provide sufficient numbers for *in vitro* cytotoxicity, a period of time known to preserve both suppressive capacity and FoxP3 expression (20). Under these conditions, sorted T_{regs} efficiently lysed target cells expressing EGFRvIII when redirected by the EGFRvIII-specific BiTE. Importantly, this effect was not detected in the presence of a nonspecific control bscAb or T_{regs} alone (Fig. 3A). Moreover, redirected T_{reg}-mediated lysis was shown to be actually dependent on the perforin-granzyme pathway, as cytotoxicity was not impacted by TRAIL or FasL blockade, but significantly abrogated in the presence of previously characterized




Figure 1. BscEGFRvIIIxCD3 activates highly purified T_{regs} but does not reverse defects in cytokine secretion and proliferation in response to stimulation. A, representative flow cytometric analysis of purified CD4⁺CD25⁺CD127^{dim/-} T_{regs} shows more than 97% purity as determined by FoxP3 and CD25 phenotypic markers. B, purified T_{regs} express elevated levels of activation markers CD69 and CD25 in response to bscEGFRvIIIxCD3 specifically in the presence of EGFRvIII-expressing tumors when compared with cells incubated with nonspecific, control BiTE. These activities were consistent and statistically significant among lymphocyte donors from three separate individuals (C). D, supernatants from wells containing U87MG.ΔEGFR, bscEGFRvIIIxCD3, and T_{regs} contained significantly lower levels inflammatory cytokines compared with wells in which responder cells consisted of purified CD4⁺CD25⁻ helper T cells (T_H). E, proliferation of T_{regs} and T_H in response to bscEGFRvIIIxCD3 and solid phase EGFRvIII as measured by ³H-thymidine incorporation shows that proliferative defects in the T_{reg} compartment persist following activation with bscEGFRvIIIxCD3. Statistical analysis in (D) and (E) were conducted in triplicate wells with lymphocytes from a single donor and all experiments were repeated twice. Horizontal bars represent a statistical significance of *P* < 0.05.




Figure 2. BscEGFRvIIIxCD3 activates T_{regs} to elevate expression of granzymes and perforin specifically in the presence of tumor cells expressing EGFRvIII. A, human PBMCs were incubated in the presence of U87MG.ΔEGFR and control BiTE (left) or EGFRvIII BiTE (right), harvested, and stained for flow cytometric analysis. CD4⁺ cells were isolated and gated for high CD25 and FoxP3 expression and then analyzed for Perf, GrA, and GrB expression with positivity determined by isotype control. Plots are representative of at least three repeated experiments. B, percent positive cells expressing Perf, GrA, or GrB were determined to be significantly elevated in the presence of EGFRvIII BiTE over nonspecific control BiTE across lymphocytes from three separate healthy donors. C, flow cytometric plot of backgated GrB-positive cells from (A) corresponds to a discrete population (dots) with dual positivity for CD25 and FoxP3. All experiments were repeated twice. Horizontal bars represent a statistical significance of *P* < 0.05 between groups of three donors each defined by the presence of either EGFRvIII-specific or control BiTE.

inhibitors of perforin- and granzyme-mediated cytotoxicity (Fig. 3B). Adding clinical relevance to these findings, infiltrating FoxP3⁺ T_{regs} in human glioma samples were actually found to coexpress detectable levels of GrB by IHC analysis (Fig. 3C). Consistent with what has been reported elsewhere, GrB expression appeared to be largely cytoplasmic while subcellular localization of FoxP3 was exhibited prominently in the nucleus (21). Overall, these data suggest that activated T_{regs} with potent effector functions may be present within glioblastomas, and could potentially serve as effector cells upon infusion with T-cell-engaging bscAb therapies *in vivo*.

In light of recent findings showing that T_{regs} may actually be required for the priming of high-avidity CD8⁺ T-cell responses (22), innovative methods to reappropriate the T_{reg} compartment without ablating these cells completely could provide an attractive alternative to currently available depletive strategies. As such, we have provided evidence and a mechanism by which T_{regs} might be redirected to kill tumor cells through engagement with a bscAb. One previous study has explored the impact of bscAbs on T_{regs} and shown that bscAb-mediated activation of T_{regs} suppresses effector cell proliferation and abrogates antitumor efficacy (23). However, the direct effects of bscAb-redirectioned T_{regs} on target tumor cells were not discussed.

Furthermore, because their work employed the use of rapamycin to expand T_{regs} *ex vivo*, an additive which is known to completely suppress GrB expression in T_{regs} (19), it may ultimately not be feasible to directly compare the results of our studies. One limitation of our work is the use of a glioblastoma cell line that may elicit low-level allogeneic responses and thus a permissive effect on the mechanisms of T_{reg} activation explored here. Further studies will be necessary to explore the degree to which this is the case, likely through the use of syngeneic mouse models or autologous human tumors.

In the current study, redirected cytotoxicity was dependent on the presence of bscEGFRvIIIxCD3; although, it is reasonable to suspect that similar results might be observed upon even endogenous TCR-specific engagement of granzyme-producing T_{regs} present in the tumor microenvironment. Supporting this,




Figure 3. T_{regs} expressing GrB are present in human glioma and possess cytotoxic activity against EGFRvIII-expressing tumor in the presence of EGFRvIII BiTE. A, upon redirection with bscEGFRvIIIxCD3, but not a nonspecific control bscAb (control), activated T_{regs} show enhanced lysis against EGFRvIII-expressing tumor [T_{reg}:target, 20:1; incubation time 18 hours; (BiTE) 10 μg/mL]. B, specific lysis against target tumor cells expressing EGFRvIII is not significantly inhibited by blockade of Fas ligand- and TRAIL-mediated apoptosis but is significantly abrogated by partial inhibitors of the granzyme-perforin pathway, Z-AAD-CMK, EGTA, and CMA. Pairwise comparisons with respect to T_{reg}, BiTE, and inhibitors of the granzyme-perforin pathway were made. All tests were conducted in triplicate wells and independently repeated. Horizontal bars represent a statistical significance between compared groups of *P* < 0.05. C, IHC analysis of human GBM shows diffuse infiltration of FoxP3⁺ T_{regs} (AEC) expressing detectable levels of GrB (DAB).

previous studies have shown that, in general, BiTE-mediated antitumor activity is indeed contact-mediated, and has the ability to induce cytolytic synapses that are indistinguishable from those naturally occurring between effector TCR and MHC (24). Thus, while our findings here were shown using a single test molecule against EGFRvIII, we expect that BiTEs targeting other tumor antigens may likewise mediate similar effects. Overall, this work advances our understanding of potential functions for suppressive immune cells in the tumor micro-environment; however, the true functional relevance of T_{reg}-mediated tumor killing remains unknown. The implications of these findings will need to be explored in future studies across broader areas of autoimmunity and immunotherapy where T_{reg} biology is relevant.

Disclosure of Potential Conflicts of Interest

No potential conflicts of interest were disclosed.

Authors' Contributions

Conception and design: B.D. Choi, P.C. Gedeon, E.A. Reap, L. Sanchez-Perez, J.H. Sampson

Development of methodology: B.D. Choi, P.C. Gedeon, G.A. Archer
Acquisition of data (provided animals, acquired and managed patients, provided facilities, etc.): B.D. Choi, P.C. Gedeon
Analysis and interpretation of data (e.g., statistical analysis, biostatistics, computational analysis): B.D. Choi, P.C. Gedeon, J.E. Herndon, G.A. Archer, E.A. Reap, L. Sanchez-Perez, D.A. Mitchell
Writing, review, and/or revision of the manuscript: B.D. Choi, P.C. Gedeon, J.E. Herndon, D.A. Mitchell, D.D. Bigner, J.H. Sampson
Administrative, technical, or material support (i.e., reporting or organizing data, constructing databases): B.D. Choi, G.A. Archer, D.D. Bigner, J.H. Sampson
Study supervision: B.D. Choi, J.H. Sampson

Grant Support

This work was supported by grants from the NIH 5R01-CA135272-04 (to J.H. Sampson), 5P50-NS020023-29 (to D.D. Bigner and J.H. Sampson), 3R25-NS065731-03S1 (to J.H. Sampson), 1F30CA177152-01 (to B.D. Choi) as well as grants from the Pediatric Brain Tumor Foundation (to D.D. Bigner and J.H. Sampson), Ben and Catherine Ivy Foundation (to J.H. Sampson), Duke Cancer Institute (to J.H. Sampson and B.D. Choi), Cancer Research Institute (to B.D. Choi), and Miami Brain Tumor Coalition (to B.D. Choi).

Received April 30, 2013; revised June 12, 2013; accepted June 28, 2013; published OnlineFirst July 5, 2013.

References

- Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJ, Janzer RC, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. *Lancet Oncol* 2009;10:459–66.
- Mellman I, Coukos G, Dranoff G. Cancer immunotherapy comes of age. *Nature* 2011;480:480–9.
- Zou W. Immunosuppressive networks in the tumour environment and their therapeutic relevance. *Nat Rev Cancer* 2005;5:263–74.
- Grossman WJ, Verbsky JW, Barchet W, Colonna M, Atkinson JP, Ley TJ. Human T regulatory cells can use the perforin pathway to cause autologous target cell death. *Immunity* 2004;21:589–601.
- Gondek DC, Lu LF, Quezada SA, Sakaguchi S, Noelle RJ. Cutting edge: contact-mediated suppression by CD4+CD25+ regulatory cells involves a granzyme B-dependent, perforin-independent mechanism. *J Immunol* 2005;174:1783–6.
- Bargou R, Leo E, Zugmaier G, Klinger M, Goebeler M, Knop S, et al. Tumor regression in cancer patients by very low doses of a T cell-engaging antibody. *Science* 2008;321:974–7.
- Choi BD, Kuan CT, Cai M, Archer GE, Mitchell DA, Gedeon PC, et al. Systemic administration of a bispecific antibody targeting EGFRvIII successfully treats intracerebral glioma. *Proc Natl Acad Sci U S A* 2013;110:270–5.
- Choi BD, Cai M, Bigner DD, Mehta AI, Kuan CT, Sampson JH. Bispecific antibodies engage T cells for antitumor immunotherapy. *Expert Opin Biol Ther* 2011;11:843–53.
- Choi BD, Archer GE, Mitchell DA, Heimberger AB, McLendon RE, Bigner DD, et al. EGFRvIII-targeted vaccination therapy of malignant glioma. *Brain Pathol* 2009;19:713–23.
- El Andaloussi A, Han Y, Lesniak MS. Prolongation of survival following depletion of CD4+CD25+ regulatory T cells in mice with experimental brain tumors. *J Neurosurg* 2006;105:430–7.
- Nishikawa R, Ji XD, Harmon RC, Lazar CS, Gill GN, Cavenee WK, et al. A mutant epidermal growth factor receptor common in human glioma confers enhanced tumorigenicity. *Proc Natl Acad Sci U S A* 1994;91:7727–31.
- Wikstrand CJ, Hale LP, Batra SK, Hill ML, Humphrey PA, Kurpad SN, et al. Monoclonal antibodies against EGFRvIII are tumor specific and react with breast and lung carcinomas and malignant gliomas. *Cancer Res* 1995;55:3140–8.
- Grossman WJ, Verbsky JW, Tollefsen BL, Kemper C, Atkinson JP, Ley TJ. Differential expression of granzymes A and B in human cytotoxic lymphocyte subsets and T regulatory cells. *Blood* 2004;104:2840–8.
- Quezada SA, Simpson TR, Peggs KS, Merghoub T, Vider J, Fan X, et al. Tumor-reactive CD4(+) T cells develop cytotoxic activity and eradicate large established melanoma after transfer into lymphopenic hosts. *J Exp Med* 2010;207:637–50.
- El Andaloussi A, Lesniak MS. An increase in CD4+CD25+FOXP3+ regulatory T cells in tumor-infiltrating lymphocytes of human glioblastoma multiforme. *Neuro Oncol* 2006;8:234–43.
- Fecci PE, Mitchell DA, Whitesides JF, Xie W, Friedman AH, Archer GE, et al. Increased regulatory T-cell fraction amidst a diminished CD4 compartment explains cellular immune defects in patients with malignant glioma. *Cancer Res* 2006;66:3294–302.
- Liu W, Putnam AL, Xu-Yu Z, Szot GL, Lee MR, Zhu S, et al. CD127 expression inversely correlates with FoxP3 and suppressive function of human CD4+ T reg cells. *J Exp Med* 2006;203:1701–11.
- Sakaguchi S, Miyara M, Costantino CM, Hafler DA. FOXP3+ regulatory T cells in the human immune system. *Nat Rev Immunol* 2010;10:490–500.
- Efimova OV, Kelley TW. Induction of granzyme B expression in T-cell receptor/CD28-stimulated human regulatory T cells is suppressed by inhibitors of the PI3K-mTOR pathway. *BMC Immunol* 2009;10:59.
- Marek N, Bieniaszewska M, Krzystyniak A, Juscinska J, Mysliwska J, Witkowski P, et al. The time is crucial for ex vivo expansion of T regulatory cells for therapy. *Cell Transplant* 2011;20:1747–58.
- Magg T, Mannert J, Ellwart JW, Schmid I, Albert MH. Subcellular localization of FOXP3 in human regulatory and nonregulatory T cells. *Eur J Immunol* 2012;42:1627–38.
- Pace L, Tempez A, Arnold-Schrauf C, Lemaitre F, Bouso P, Fetter L, et al. Regulatory T cells increase the avidity of primary CD8+ T cell responses and promote memory. *Science* 2012;338:532–6.
- Koristka S, Cartellieri M, Theil A, Feldmann A, Arndt C, Stamova S, et al. Retargeting of human regulatory T cells by single-chain bispecific antibodies. *J Immunol* 2012;188:1551–8.
- Offner S, Hofmeister R, Romaniuk A, Kufer P, Baeuerle PA. Induction of regular cytolytic T cell synapses by bispecific single-chain antibody constructs on MHC class I-negative tumor cells. *Mol Immunol* 2006;43:763–71.